Document is current
Any future updates will be listed below
-
Authors
Boleto, Gonçalo
Guignabert, Christophe
Pezet, Sonia
Cauvet, Anne
Sadoine, Jérémy
Tu, Ly
Nicco, Carole
Gobeaux, Camille
Batteux, Frédéric
Allanore, Yannick
Avouac, Jérôme https://orcid.org/0000-0002-2463-218X
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb (: study drug was supplied by Bristol-Myers Squibb, Co.)
- License Information
-
More Information
Article History
Received: 30 January 2018
Accepted: 1 August 2018
First Online: 29 August 2018
Ethics approval
: All animals were treated in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by INSERM, and approval was granted by the Ethics Committee of our University.
: Not applicable.
: JA has had a consultancy relationship and/or has received research funding for the treatment of systemic sclerosis from Actelion, Roche, Pfizer, and Bristol-Myers Squibb. YA has had a consultancy relationship and/or has received research funding for the treatment of systemic sclerosis from Actelion, Bayer, Biogen Idec, Bristol-Myers Squibb, Genentech/Roche, Inventiva, Medac, Pfizer, Sanofi Genzyme, Servier, and UCB. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
